Immunological aspects of metronomic chemotherapy regimens
- Autores: Efremova N.A1,2, Novik A.V1,2, Zozulya A.Y.1, Nekhaeva T.L1, Danilova A.B1, Emelyanova N.V1, Girdyuk D.V1, Gafton G.I1, Baldueva I.A1
-
Afiliações:
- N.N. Petrov National Medical Research Center of Oncology
- St. Petersburg State Pediatric Medical University
- Edição: Volume 28, Nº 7 (2021)
- Páginas: 81-86
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313183
- DOI: https://doi.org/10.18565/pharmateca.2021.7.81-86
- ID: 313183
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
N. Efremova
N.N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical University
Email: petrovcenter.celltech@gmail.com
St. Petersburg, Russia
A. Novik
N.N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
A. Zozulya
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
T. Nekhaeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Danilova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
N. Emelyanova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
D. Girdyuk
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
G. Gafton
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
I. Baldueva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Bibliografia
- Jo V.Y, Fletcher C.D.M. WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology. 2014;46(2):95-104. Dot 10.1097/PAT.0000000000000050.
- Авдонкина Н.А., Данилова А.Б., Нехаева Т.Л., Балдуева И.А.Современные представления о клональной эволюции сарком. Вопросы онкологии. 2019;65(6):798-806.
- Kareva I., Waxman D. J, Klement G. L. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer letters. 2015;358(2):100-6. doi: 10.1016/j.canlet.2014.12.039.
- Butt A.Q., Mills K.H.G. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene. 2014;33(38):4623-31. doi: 10.1038/onc.2013.432.
- Pipia N., et al. Autologous dendritic-cell vaccine based on cancer-testis antigens ‘CaTeVac' in the treatment of soft tissue sarcoma. Ann Oncol. 2018;29:viii410-viii411. doi: 10.1093/annonc/ mdy288.026.
- Новик А.В., Гирдюк Д.В., Кузнецова А.И., Балдуева И.А. Способ определения значимости различий результатов измерения субпопуляции лимфоцитов методом проточной цитофлюориметрии. Патент № RU 2720411C1 от29.04.2020.
- Zhong H., et al. Low dose cyclophosphamide modulates tumor microenvironment by TGF-fi signaling pathway. Int J MolSci. 2020;21(3):957. doi: 10.3390/ijms21030957.
- Ghiringhelli F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641-48. doi: 10.1007/s00262-006-0225-8.
- Schmittnaegel M., et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):eaak9670. Doi: 10.1126/ scitranslmed.aak9670.
- Балдуева И.А., Данилова А.Б., Новик А.В. и др. Дендритные клетки, активированные раковотестикулярными антигенами (РТА+), в лечении метастатических сарком мягких тканей. Вопросы онкологии. 2014;60(6):700-6.
- Danilova A., et al. Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells. Clin Sarcoma Res. 2020;10:3. doi: 10.1186/s13569-020-0125-2.
- Desar I.M.E., Fleuren E.D.G., van der Graaf W.T.A. Systemic Treatment for Adults with Synovial Sarcoma. Curr Treat Option Oncol. 2018;19(2):13. doi: 10.1007/s11864-018-0525-1.